INDUSTRY NEWS: Neptune and Acasti Pharma to present study results at ATVB 2010

Neptune Technologies & Bioressources Inc. and Acasti Pharma Inc. announce the acceptance for presentation of preclinical study results at the council for Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2010 Scientific Sessions Meeting of the American Heart Association to be held April 8-10 in San Francisco, CA.

__________________

Acasti Pharma Inc. to present at the ATVB 2010 council of the American Heart Association

Significant positive lipid management effects will be presented

Laval, Québec, CANADA –April 8 , 2010 – Neptune Technologies & Bioressources Inc. (“Neptune”) (NASDAQ.NEPT - TSX.V.NTB) and Acasti Pharma Inc. (“Acasti”) announce the acceptance for presentation of preclinical study results at the council for Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2010 Scientific Sessions Meeting of the American Heart Association to be held April 8-10 in San Francisco, CA.

The results of the study entitled "CaPre™, an Omega-3: Phospholipid, Managing Dyslipidemia in Three Murine Phenotypes " will be presented by Dr. Steven J. Adelman, Ph.D., FAHA, CEO/Founder of Vascular Strategies LLC. This study, conducted in collaboration with Professor Daniel Rader, University of Pennsylvania School of Medicine, and Dr. Steven J. Adelman, evaluates the mechanism of action of Acasti’s prescription drug candidate (omega-3 phospholipid “CaPre™”) for the treatment of dyslipidemia and cardio-metabolic disorders.

CaPre™ was shown to be effective in beneficially modulating the lipid profile of healthy and diseased mice with high cholesterol, obesity and diabetes. CaPre™ significantly reduced triglycerides (60%) and bad cholesterol - LDL (28%) while simultaneously increasing good cholesterol - HDL (25%).

“We are all very pleased that our data has been accepted by the American Heart Association, through a peer reviewed process, allowing us to introduce Acasti in the medical scientific community with our participation in the ATVB 2010 sessions” said Dr. Tina Sampalis, President of Acasti Pharma Inc. “It is a great privilege to work with distinguished scientists like Prof. Rader and Dr. Adelman. This is the first of three studies we are working on together, and we are looking forward to expanding to further preclinical and clinical studies soon.”

SOURCE: Neptune Press Release